17 April 2025 – London, UK – Prosemble is proud to announce its selection for the Cancer Tech Accelerator, a prestigious programme designed to support groundbreaking technologies with the potential to transform the early detection, diagnosis, monitoring, or treatment of cancer. The Cancer Tech Accelerator is a joint initiative by Cancer Research Horizons and Cancer Research UK, with grant support from several of the UK’s leading cancer charities. The programme provides a unique platform to help translate original scientific research into commercially viable start-ups. By joining the Accelerator, Prosemble will gain access to expert guidance, mentorship, and the opportunity to test its technology with world-leading cancer specialists. This support will significantly advance the development and potential impact of Prosemble’s platform in the oncology space. “We’re honoured to be selected for the Cancer Tech Accelerator,” said Dr. Julien Bergeron, CEO/CSO at Prosemble. “This opportunity will allow us to accelerate our mission to improve outcomes for patients through cutting-edge biomedical innovation.”